First Affirmative Financial Network Has $244,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

First Affirmative Financial Network grew its position in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 16.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,166 shares of the biopharmaceutical company’s stock after acquiring an additional 442 shares during the period. First Affirmative Financial Network’s holdings in Gilead Sciences were worth $244,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Arrowstreet Capital Limited Partnership raised its stake in shares of Gilead Sciences by 324.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after acquiring an additional 13,764,169 shares during the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $1,115,186,000. Moneta Group Investment Advisors LLC raised its position in Gilead Sciences by 96,759.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 10,111,194 shares of the biopharmaceutical company’s stock worth $868,046,000 after purchasing an additional 10,100,755 shares during the last quarter. Renaissance Technologies LLC boosted its position in Gilead Sciences by 70.6% in the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock valued at $921,006,000 after buying an additional 6,410,047 shares during the last quarter. Finally, FMR LLC increased its stake in shares of Gilead Sciences by 27.2% in the 1st quarter. FMR LLC now owns 20,909,082 shares of the biopharmaceutical company’s stock valued at $1,734,826,000 after buying an additional 4,470,179 shares during the period. 82.33% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the transaction, the chief financial officer now owns 107,587 shares in the company, valued at approximately $8,606,960. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Andrew D. Dickinson sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the sale, the chief financial officer now owns 107,587 shares in the company, valued at approximately $8,606,960. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 1,501 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total transaction of $115,561.99. Following the completion of the transaction, the insider now directly owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on GILD. HSBC assumed coverage on Gilead Sciences in a research note on Wednesday, September 6th. They set a “reduce” rating and a $71.00 price target on the stock. Truist Financial reiterated a “buy” rating and set a $91.00 price target on shares of Gilead Sciences in a research report on Wednesday, September 6th. Piper Sandler cut their price objective on shares of Gilead Sciences from $105.00 to $100.00 and set an “overweight” rating on the stock in a report on Monday, July 24th. BMO Capital Markets lowered their target price on shares of Gilead Sciences from $100.00 to $95.00 in a report on Tuesday, July 18th. Finally, Cantor Fitzgerald cut their price target on Gilead Sciences from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 19th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $90.05.

Check Out Our Latest Analysis on Gilead Sciences

Gilead Sciences Price Performance

GILD stock opened at $75.67 on Friday. The stock has a 50-day moving average price of $77.28 and a two-hundred day moving average price of $78.79. Gilead Sciences, Inc. has a 1 year low of $61.44 and a 1 year high of $89.74. The stock has a market cap of $94.29 billion, a PE ratio of 17.40, a price-to-earnings-growth ratio of 0.83 and a beta of 0.37. The company has a current ratio of 1.02, a quick ratio of 0.91 and a debt-to-equity ratio of 1.07.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.30). Gilead Sciences had a return on equity of 37.53% and a net margin of 20.03%. The firm had revenue of $6.60 billion for the quarter, compared to the consensus estimate of $6.45 billion. During the same quarter in the previous year, the business posted $1.58 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Equities analysts forecast that Gilead Sciences, Inc. will post 6.64 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 3.96%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.97%.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.